Literature DB >> 2874735

Systemic and renal vasodilation after beta-adrenoceptor blockade with pindolol: a hemodynamic study on the onset and maintenance of its antihypertensive effect.

A H van den Meiracker, A J Man in 't Veld, H J Ritsema van Eck, M A Schalekamp.   

Abstract

Pindolol, a beta blocker with considerable partial agonist activity (PAA), was studied in 10 hypertensive subjects. The maximal fall in mean arterial pressure (MAP) was seen 3 to 4 hours after oral dosing with 10 mg of pindolol (-15 +/- 3%, mean +/- SEM). This was caused by a reduction in total peripheral resistance (TPR), which amounted to 25 +/- 4% after 24 hours. Cardiac output increased by 16 +/- 5%. Cardiac filling pressures and pulmonary artery pressure did not change. Increasing the dose of pindolol, from 5 mg twice a day to 15 mg twice a day over a 3-week period, caused no further change in MAP. After 3 weeks, the fall in MAP (-11 +/- 2%) was maintained by reduced TPR (-26 +/- 6%), whereas cardiac output and stroke volume were increased by 16 +/- 6% and 26 +/- 6%. Renal blood flow and glomerular filtration rate did not change. Beta blockers devoid of PAA lower cardiac output, whereas the elevated TPR in hypertension is unchanged. The hemodynamic profile of pindolol essentially differs from that of beta blockers devoid of PAA.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874735     DOI: 10.1016/0002-8703(86)90277-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

1.  Acute systemic and antiischemic effects of epanolol in patients with coronary artery disease.

Authors:  E H Venneker; W J Remme; D C van Hoogenhuyze; X H Krauss; G L Bartels; D A Kruijssen; C J Storm; D van Schelven
Journal:  Cardiovasc Drugs Ther       Date:  1994-04       Impact factor: 3.727

2.  Sleep patterns and blood pressure variability in patients with pure autonomic failure.

Authors:  J H Tulen; A J Man in 't Veld; H G van Steenis; K Mechelse
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.